Osimertinib (Tagrisso®)
Dokument
Fact Sheet
Spezifizierung
Lungenkarzinom, nicht-kleinzellig (NSCLC)
» EGFRmut
» Stadium IB-IIIA
Stand
Juli 2021
Dies ist die aktuell gültige Version des Dokuments
1Adjuvant Targeted Therapy, NSCLC EGFRmut, Stage IB-IIIA
1 N - number of patients5 OS - overall survival in months8 EFS - Event-Free Survival14 results for control, results for new therapy15 hazard ratio for new therapy18 n. r. – median not reached